Press Releases

Press Releases

Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing

BioEleven Partnership Image
 

Incheon, S. Korea, 20 October 2020 – Samsung Biologics (207940.KS) has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer. 

 

Under this agreement, Samsung Biologics will provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing as well as IND filing support.

 

“Partnering with BioEleven reinforces the key value of our CDO business model: to support our clients with faster and better services in their efforts to help patients in need all around the world,” said Dr. Tae Han Kim, CEO of Samsung Biologics. “We thank BioEleven for putting trust in our services, and look forward to seeing what this partnership will accomplish.”

BioEleven Partnership Image
 

Incheon, S. Korea, 20 October 2020 – Samsung Biologics (207940.KS) has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer. 

 

Under this agreement, Samsung Biologics will provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing as well as IND filing support.

 

“Partnering with BioEleven reinforces the key value of our CDO business model: to support our clients with faster and better services in their efforts to help patients in need all around the world,” said Dr. Tae Han Kim, CEO of Samsung Biologics. “We thank BioEleven for putting trust in our services, and look forward to seeing what this partnership will accomplish.”

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION